Loss of LRF in prostate cancer cells activates SOX9, a key driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition [303]. Here, SOX9 is linked to prostate carcinoma.